Statin as a therapeutic agent in gastroenterological cancer

doi:10.4251/wjgo.v14.i1.110

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3889)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

206

WORD

126

HTML

2251

Figures (1-2)

249

Tables (1-2)

206

Sum=3038

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

307

Download

544

Sum=851

Jan 15, 2022 (publication date) through Jul 16, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Jan 15, 2022; 14(1): 110-123
Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.110

Full Size Figure Download Figure

Figure 1 The mevalonate pathway and the SREBPs-mediated feedback response. SREBP: Sterol regulatory element-binding protein; LDL: Low density lipoprotein; LDLR: Low density lipoprotein receptor; HMGCR: 3-hydroxy-3-methylglutaryl coenzyme A reductase.

Citation: Uemura N, Hayashi H, Baba H. Statin as a therapeutic agent in gastroenterological cancer. World J Gastrointest Oncol 2022; 14(1): 110-123
URL: https://www.wjgnet.com/1948-5204/full/v14/i1/110.htm
DOI: https://dx.doi.org/10.4251/wjgo.v14.i1.110